Giant Cell Tumor of Bone Clinical Trial
Official title:
Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series
NCT number | NCT04002817 |
Other study ID # | Pediatric GCTB |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 5, 2019 |
Est. completion date | June 30, 2020 |
Verified date | June 2019 |
Source | Istituto Ortopedico Rizzoli |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
single institution cases series review of histological and clinical data of young patient with Giant Cell Tumors
Status | Completed |
Enrollment | 18 |
Est. completion date | June 30, 2020 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 15 Years |
Eligibility | Inclusion Criteria: 1. Male and female patients under 15 years old treated at Rizzoli Institute from 01 January 1982 to 31 December 2018. 2. Diagnosis of giant cell tumor of bone, aneurysmatic bone cysts with solid features and giant cell reparative granuloma. 3. Histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis 4. Written informed consent prior to any study-specific analysis and/or data collection Exclusion Criteria: 1. Patients with histological diagnosis different from diagnosis of giant cell tumor, aneurysmatic bone cysts with solid features, and giant cell reparative granuloma. 2. Patients with no available material for additional immunohistochemical and molecular analysis |
Country | Name | City | State |
---|---|---|---|
Italy | Istituto Ortopedico Rizzoli | Bologna |
Lead Sponsor | Collaborator |
---|---|
Istituto Ortopedico Rizzoli |
Italy,
Al-Ibraheemi A, Inwards CY, Zreik RT, Wenger DE, Jenkins SM, Carter JM, Boland JM, Rose PS, Jin L, Oliveira AM, Fritchie KJ. Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients. Am J Surg Pat — View Citation
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987 Jan;69(1):106-14. — View Citation
Dahlin DC, Cupps RE, Johnson EW Jr. Giant-cell tumor: a study of 195 cases. Cancer. 1970 May;25(5):1061-70. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | selection and review of 50 cases of young patients with Giant Cell Tumor of bone. | Investigators will review all the medical records, radiological imaging, and histological slides of all cases in order to collect the largest pediatric series. | at baseline (Day0) | |
Secondary | analysis of H3F3A mutation expression on tissue tumor material | In all cases with enough available material, immunohistochemistry will be performed on tumor tissue material. Histone 3.3 (H3.3) genes, and H3F3A mutation will be analyzed with immunohistochemistry and/or by allele specific-PCR analysis in order to confirm that the lesions are a giant cell tumors of bone occurring in a non-canonic age group (skeletally immature patients). | at baseline (Day0) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Active, not recruiting |
NCT04255576 -
Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone
|
Phase 1/Phase 2 | |
Completed |
NCT03301857 -
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
|
Phase 4 | |
Completed |
NCT05402865 -
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
|
||
Recruiting |
NCT03295981 -
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
|
Phase 3 | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Recruiting |
NCT03259152 -
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
|
Phase 3 | |
Recruiting |
NCT05595603 -
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
|
Phase 2 | |
Not yet recruiting |
NCT03358212 -
Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China
|
N/A | |
Completed |
NCT00396279 -
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
|
Phase 2 | |
Terminated |
NCT00889590 -
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
|
Phase 2 | |
Recruiting |
NCT04586660 -
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
|
Phase 4 | |
Active, not recruiting |
NCT03449108 -
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
|
Phase 2 | |
Not yet recruiting |
NCT05813665 -
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
|
Phase 3 | |
Completed |
NCT02996734 -
Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment
|
N/A |